

In vivo molecular diagnostics in Alzheimer's Disease (LeARN)

 consortiapedia.fastercures.org/consortia/learn/

Research Areas



At a Glance

- Status: **Completed Consortium**
- Year Launched: **2008**
- Initiating Organization: **Center for Translational Molecular Medicine (CTMM)**
- Initiator Type: **Government**
- Location: **Europe**

Abstract

Mission

Age-related cognitive impairment and dementia impose an increasing burden on aging Western societies in terms of diminished quality-of-life and high healthcare costs (approximately €3 billion annually in the Netherlands). Memory loss is often regarded by patients as an indication that they may have Alzheimer's Disease (AD), although in practice it is also a symptom of many far less serious conditions. An important challenge is therefore to differentiate those patients who will not develop dementia (who can thus be comforted) from those who will develop full-blown AD with dementia (for whom healthcare should be provided).

This project aims to develop new instruments with which to make an earlier and more reliable diagnosis of AD during life and create the conditions for an effective evaluation of novel medication therapies for AD patients.

These aims will be achieved by developing the following:

Consortium History

July 2008: Project began

Links/Social Media Feed

Other website <https://www.myctmm.nl/pro1/general/start.asp?i=4&j=1&k=0&p=0&itemid=73&folder=Neurodegenerative%20diseases&title=Learn>

Points of Contact

Principal Investigator

M. A. van Buchem

CTMM Program Manager

Henny Bruinewoud

Sponsors & Partners

BAC

Cyclotron

Leids Universitair Centrum

Maastricht University Medical Center

Merck-Sharpe & Dome

Philips Electronics

To-BBB

Universitair Medisch Centrum St. Radboud

Virtual Proteins

VU Medisch Centrum

Updated: 04/15/2016